Last reviewed · How we verify
Platelet Rich Plasma for 4 sessions
Platelet Rich Plasma, offered by Skin Care and Laser Physicians of Beverly Hills, is a marketed treatment involving four sessions, with a key composition patent expiring in 2028. The treatment leverages the company's established presence in aesthetic medicine, providing a non-invasive option for skin rejuvenation. The primary risk is the lack of robust clinical trial data to support efficacy claims, which may limit broader market acceptance.
At a glance
| Generic name | Platelet Rich Plasma for 4 sessions |
|---|---|
| Sponsor | Skin Care and Laser Physicians of Beverly Hills |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles Tendinopathy (NA)
- PRP Plus Fractional CO₂ Laser for Acne Scars (NA)
- PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study (PHASE2)
- PRP Exosomes Therapy for Erectile Dysfunction (PHASE2)
- PRP Versus PRF Versus Conventional Treatment in Chronic Non-healing Skin Ulcers (NA)
- Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia (PHASE2)
- Effectiveness of Platelet-rich Plasma Treatment of Knee Osteoarthritis (PHASE2)
- Intra Articular Injection of Ozone With Corticosteroids vs PRGF in Knee Osteoarthritis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: